Search scope:
排序: Display mode:
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
Frontiers of Medicine 2020, Volume 14, Issue 6, Pages 711-725 doi: 10.1007/s11684-020-0808-3
Keywords: chimeric antigen receptor T (CAR-T) cell lymphoma cytokine release syndrome (CRS) immune effector cell-associated
Chimeric antigen receptor T cell therapies for acute myeloid leukemia
Bin Gu, Jianhong Chu, Depei Wu
Frontiers of Medicine 2020, Volume 14, Issue 6, Pages 701-710 doi: 10.1007/s11684-020-0763-z
Keywords: acute myeloid leukemia CAR T immunotherapy
Frontiers of Medicine 2022, Volume 16, Issue 2, Pages 285-294 doi: 10.1007/s11684-021-0843-8
Keywords: CAR-T cell therapy refractory diffuse large B-cell lymphoma cytokine release syndrome dose-limiting
Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues Review
Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang
Engineering 2019, Volume 5, Issue 1, Pages 122-131 doi: 10.1016/j.eng.2018.12.003
Adoptive cell therapy using chimeric antigen receptor T (CAR-T) cells, which is a promising cancerCAR-T cells are genetically modified T cells that can specifically recognize tumor specific antigensAt present, exciting results are being achieved in clinical applications of CAR-T cells for patientsThe research and development of CAR-T cells for various targets and for the treatment of solid tumorsthe general principles of and key issues regarding the quality control and nonclinical research of CAR-T
Keywords: Chimeric antigen receptor T cells Quality control Nonclinical research Safety Efficacy Clinical
Frontiers of Medicine 2023, Volume 17, Issue 4, Pages 699-713 doi: 10.1007/s11684-022-0972-8
Keywords: anti-CD19 chimeric antigen receptor T immunotherapy diffuse large B cell lymphoma tumor microenvironment
CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a
Frontiers of Medicine 2022, Volume 16, Issue 3, Pages 322-338 doi: 10.1007/s11684-021-0901-2
Keywords: cancer immunotherapy chimeric antigen receptor solid tumors tumor-associated antigen glycosylation O-glycans adoptive cell therapy
Management of cytokine release syndrome related to CAR-T cell therapy
Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xiaohu Fan, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Qiuchuan Zhuang, Wanggang Zhang, Wanhong Zhao, Aili He
Frontiers of Medicine 2019, Volume 13, Issue 5, Pages 610-617 doi: 10.1007/s11684-019-0714-8
Keywords: chimeric antigen receptor T cell cytokine release syndrome tocilizumab
Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang
Frontiers of Medicine 2020, Volume 14, Issue 6, Pages 786-791 doi: 10.1007/s11684-020-0751-3
Keywords: anti-CD19 chimeric antigen receptor T cell soft tissue bone marrow relapsed or refractory non-Hodgkin
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen
Frontiers of Medicine 2019, Volume 13, Issue 1, Pages 57-68 doi: 10.1007/s11684-019-0683-y
Keywords: chimeric antigen receptor T cells epidermal growth factor receptor lung cancer immunotherapy tumor immunolog
Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang
Frontiers of Medicine 2020, Volume 14, Issue 6, Pages 811-815 doi: 10.1007/s11684-020-0740-6
Keywords: anti-CD19 chimeric antigen receptor T cells mantle cell lymphoma relapsed or refractory long-term follow-up
Sabrina Wright, Conor Hennessy, Joanna Hester, Fadi Issa
Engineering 2022, Volume 10, Issue 3, Pages 30-43 doi: 10.1016/j.eng.2021.10.018
Chimeric antigen receptors (CARs) are a breakthrough in genetic engineering that have revolutionizedCells expressing these receptors are rerouted to a predefined target by the inclusion of an antigen-specificbinding region within the synthetic CAR construct.In contrast to conventional T cells (Tconvs), regulatory T cells (Tregs) play a major role in suppressingCAR expression within Tregs has been proposed as a therapy for autoimmune and inflammatory diseases,
Keywords: Chimeric antigen receptors T cell Treg Alloimmunity Bioengineering Transplant Autoimmunity
Engineered T Cell Therapies from a Drug Development Viewpoint Review
Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey
Engineering 2019, Volume 5, Issue 1, Pages 140-149 doi: 10.1016/j.eng.2018.11.010
Keywords: Engineered T cell therapies Chimeric antigen receptor Drug development process Biomarkers CAR19
Adoptive cell transfer therapy for hepatocellular carcinoma
Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen
Frontiers of Medicine 2019, Volume 13, Issue 1, Pages 3-11 doi: 10.1007/s11684-019-0684-x
Keywords: adoptive cell transfer therapy hepatocellular carcinoma T cell chimeric antigen receptor immunotherapy
CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
Yongping Zhang, Xingying Zhang, Chen Cheng, Wei Mu, Xiaojuan Liu, Na Li, Xiaofei Wei, Xiang Liu, Changqing Xia, Haoyi Wang
Frontiers of Medicine 2017, Volume 11, Issue 4, Pages 554-562 doi: 10.1007/s11684-017-0543-6
T cells engineered with chimeric antigen receptor (CAR) have been successfully applied to treat advancedThe immunosuppressive nature of tumor microenvironment is considered one of the key factors limiting CAR-TWe successfully generated LAG-3 knockout T and CAR-T cells with high efficiency using LAG-3 knockout CAR-T cells displayed robust antigen-specific antitumor activity incell culture and in murine xenograft model, which is comparable to standard CAR-T cells.
Keywords: CAR-T CRISPR-Cas9 LAG-3
Emerging immunological strategies: recent advances and future directions
Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 805-828 doi: 10.1007/s11684-021-0886-x
Keywords: cancer immunotherapy bispecific antibodies small molecules chimeric antigen receptor T therapy cancer
Title Author Date Type Operation
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
Journal Article
Chimeric antigen receptor T cell therapies for acute myeloid leukemia
Bin Gu, Jianhong Chu, Depei Wu
Journal Article
Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients
Journal Article
Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues
Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang
Journal Article
Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy
Journal Article
CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a
Journal Article
Management of cytokine release syndrome related to CAR-T cell therapy
Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xiaohu Fan, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Qiuchuan Zhuang, Wanggang Zhang, Wanhong Zhao, Aili He
Journal Article
involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimericantigen receptor T cell therapy
Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang
Journal Article
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen
Journal Article
Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma
Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang
Journal Article
Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in
Sabrina Wright, Conor Hennessy, Joanna Hester, Fadi Issa
Journal Article
Engineered T Cell Therapies from a Drug Development Viewpoint
Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey
Journal Article
Adoptive cell transfer therapy for hepatocellular carcinoma
Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen
Journal Article
CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
Yongping Zhang, Xingying Zhang, Chen Cheng, Wei Mu, Xiaojuan Liu, Na Li, Xiaofei Wei, Xiang Liu, Changqing Xia, Haoyi Wang
Journal Article